RBC Capital Markets initiates coverage on Tandem Diabetes Care (TNDM) with an Outperform rating and $65 price target, citing ...

Analyst Jeff Johnson from Robert W. Baird reiterated a Hold rating on Tandem Diabetes Care (TNDM – Research Report) and increased the ...

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2 insulin pump with Control-IQ automated insulin delivery ...

Tandem Diabetes Care has announced that its t:slim X2 insulin pump, featuring Control-IQ automated insulin delivery technology, received approval for use with the ultra-rapid-acting insulin ...

connect mobile app by Tandem Diabetes Care, Inc. (Nasdaq: TNDM). The recall, originally issued in March 2024, addresses a critical issue causing rapid depletion of the t:slim X2 insulin pump ...

Research on CSII therapy began in the late 1970s, with a strong resurgence in the 1990s after technological advances in blood glucose monitoring devices and insulin delivery systems. In the ...

Objective: To evaluate the safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes. Research Design and Methods: All 95 patients who began insulin pump ...

RBC Capital Markets initiated coverage on Tandem Diabetes Care ... the rise of GLP-1s class drugs is not a major threat to insulin pump adoption. GLP-1 drugs such as Novo Nordisk A/S‘ (NYSE ...

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2 insulin pump with Control-IQ automated insulin delivery (AID) ...